Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPLORING: Penpulimab and Anlotinib with XELOX for ctDNA+ Gastric Cancer
NCT05494060Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Mar 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of penpulimab, anlotinib in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Jiangsu Provincial People's Hospital. Started Mar 2022; status: recruiting.
02
Drugs
penpulimabanlotinib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05494060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05494060.